Matches in SemOpenAlex for { <https://semopenalex.org/work/W3012007280> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W3012007280 endingPage "88" @default.
- W3012007280 startingPage "82" @default.
- W3012007280 abstract "Objectives: Pazopanib is an orally administered drug and has approval for the treatment of advanced Soft Tissue Sarcomas (aSTS). The absorption of pazopanib is pH-dependent. Acid-Reducing drugs such as proton pump inhibitors (PPI) may reduce the bioavailability of pazopanib. The primary purpose of this study was to assess whether the use of concomitant PPI and pazopanib had negative effects on survival outcomes. Methods: In this retrospective cross-sectional study, age ≥18 years, having histologically proven STS, receiving pazopanib at least one day, and availability of information about the use of PPI during pazopanib treatment were the inclusion criteria. Patients with adipocytic sarcoma were excluded. Results: A total of 46 eligible patients were assessed in this study. Thirty-one patients used concomitant PPI and pazopanib, 17 of them frequently used PPI, and the others occasionally. Fifteen patients never used concomitant PPI and pazopanib. The median progression-free survival (PFS) was 2.76 months, and the median overall survival (OS) was 7.39 months for patients who never used concomitant PPI and pazopanib. Also, the median PFS was 5.22 months, and the median OS was 14.52 months for patients who used concomitant PPI and pazopanib. In univariate analysis; using concomitant PPI (p=0.049) and primarily uterine located tumors (p=0.038) were significant parameters for PFS. In multivariate logistic regression analysis; both of using concomitant PPI (Wald=6.02; p=0.014) and primarily uterine located tumors (Wald=5.69; p=0.017) retained their association with longer PFS. No parameter was significant for OS. Conclusions: We showed that the use of concomitant PPI and pazopanib was associated with improved PFS. These results may help guide clinicians and researchers for allowing patients co-administrating PPI and pazopanib, especially when treating or investigating patients with dyspeptic symptoms." @default.
- W3012007280 created "2020-03-23" @default.
- W3012007280 creator A5017203819 @default.
- W3012007280 creator A5019991786 @default.
- W3012007280 creator A5063093037 @default.
- W3012007280 creator A5065251701 @default.
- W3012007280 creator A5068468956 @default.
- W3012007280 creator A5080834334 @default.
- W3012007280 date "2020-03-18" @default.
- W3012007280 modified "2023-09-30" @default.
- W3012007280 title "The Concomitant Use Of Proton Pump Inhibitors And Pazopanib In Patients With Soft-Tissue Sarcoma: Is It Really To Be Avoided?" @default.
- W3012007280 doi "https://doi.org/10.5798/dicletip.706025" @default.
- W3012007280 hasPublicationYear "2020" @default.
- W3012007280 type Work @default.
- W3012007280 sameAs 3012007280 @default.
- W3012007280 citedByCount "0" @default.
- W3012007280 crossrefType "journal-article" @default.
- W3012007280 hasAuthorship W3012007280A5017203819 @default.
- W3012007280 hasAuthorship W3012007280A5019991786 @default.
- W3012007280 hasAuthorship W3012007280A5063093037 @default.
- W3012007280 hasAuthorship W3012007280A5065251701 @default.
- W3012007280 hasAuthorship W3012007280A5068468956 @default.
- W3012007280 hasAuthorship W3012007280A5080834334 @default.
- W3012007280 hasBestOaLocation W30120072801 @default.
- W3012007280 hasConcept C121608353 @default.
- W3012007280 hasConcept C126322002 @default.
- W3012007280 hasConcept C142724271 @default.
- W3012007280 hasConcept C143998085 @default.
- W3012007280 hasConcept C144301174 @default.
- W3012007280 hasConcept C2778256501 @default.
- W3012007280 hasConcept C2778439243 @default.
- W3012007280 hasConcept C2778629024 @default.
- W3012007280 hasConcept C2779384505 @default.
- W3012007280 hasConcept C2779490328 @default.
- W3012007280 hasConcept C38180746 @default.
- W3012007280 hasConcept C71924100 @default.
- W3012007280 hasConcept C90924648 @default.
- W3012007280 hasConceptScore W3012007280C121608353 @default.
- W3012007280 hasConceptScore W3012007280C126322002 @default.
- W3012007280 hasConceptScore W3012007280C142724271 @default.
- W3012007280 hasConceptScore W3012007280C143998085 @default.
- W3012007280 hasConceptScore W3012007280C144301174 @default.
- W3012007280 hasConceptScore W3012007280C2778256501 @default.
- W3012007280 hasConceptScore W3012007280C2778439243 @default.
- W3012007280 hasConceptScore W3012007280C2778629024 @default.
- W3012007280 hasConceptScore W3012007280C2779384505 @default.
- W3012007280 hasConceptScore W3012007280C2779490328 @default.
- W3012007280 hasConceptScore W3012007280C38180746 @default.
- W3012007280 hasConceptScore W3012007280C71924100 @default.
- W3012007280 hasConceptScore W3012007280C90924648 @default.
- W3012007280 hasLocation W30120072801 @default.
- W3012007280 hasLocation W30120072802 @default.
- W3012007280 hasLocation W30120072803 @default.
- W3012007280 hasOpenAccess W3012007280 @default.
- W3012007280 hasPrimaryLocation W30120072801 @default.
- W3012007280 hasRelatedWork W1805852575 @default.
- W3012007280 hasRelatedWork W2026017440 @default.
- W3012007280 hasRelatedWork W2318766411 @default.
- W3012007280 hasRelatedWork W2566089246 @default.
- W3012007280 hasRelatedWork W2912245247 @default.
- W3012007280 hasRelatedWork W2940672269 @default.
- W3012007280 hasRelatedWork W3194091392 @default.
- W3012007280 hasRelatedWork W3198106554 @default.
- W3012007280 hasRelatedWork W4361934983 @default.
- W3012007280 hasRelatedWork W4362407017 @default.
- W3012007280 isParatext "false" @default.
- W3012007280 isRetracted "false" @default.
- W3012007280 magId "3012007280" @default.
- W3012007280 workType "article" @default.